2014
Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease: The TEAM-AD VA Cooperative Randomized Trial
Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, Love S, Schellenberg GD, McCarten JR, Malphurs J, Prieto S, Chen P, Loreck DJ, Trapp G, Bakshi RS, Mintzer JE, Heidebrink JL, Vidal-Cardona A, Arroyo LM, Cruz AR, Zachariah S, Kowall NW, Chopra MP, Craft S, Thielke S, Turvey CL, Woodman C, Monnell KA, Gordon K, Tomaska J, Segal Y, Peduzzi PN, Guarino PD. Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease: The TEAM-AD VA Cooperative Randomized Trial. JAMA 2014, 311: 33-44. PMID: 24381967, PMCID: PMC4109898, DOI: 10.1001/jama.2013.282834.Peer-Reviewed Original ResearchConceptsAlpha-tocopherol groupModerate Alzheimer's diseaseIU/dAlzheimer's diseaseFunctional declineTocopherol groupAlpha-tocopherolVitamin EAlzheimer's Disease Cooperative Study/ActivitiesVeterans Affairs Medical CenterInventory scoresSlow functional declineSerious adverse eventsSevere Alzheimer's diseaseMemantine groupCause mortalityPlacebo groupSecondary outcomesAdverse eventsRandomized trialsClinical progressionCombination groupCaregiver burdenClinical trialsSlow progression
2013
Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O'Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P. Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy. New England Journal Of Medicine 2013, 369: 1892-1903. PMID: 24206457, DOI: 10.1056/nejmoa1303154.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseGlomerular filtration rateAngiotensin receptor blockersAcute kidney injuryCombination therapyEnd pointKidney injuryDiabetic nephropathyPrimary end-point eventAngiotensin-converting enzyme inhibitorPrimary end pointSecondary end pointsCombination therapy groupRenal end pointsRisk of hyperkalemiaEnd-point eventsType 2 diabetesBody surface areaConclusion Combination therapyAngiotensin inhibitionCardiovascular eventsMonotherapy groupAdverse eventsCreatinine ratioRenal disease